Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Array Biopharma

- PMLiVE

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Has potential in cardiovascular and metabolic diseases

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

Pfizer goes big on gene therapy with $500m facility spend

Continues to build on its growing gene therapy business

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

- PMLiVE

Sarepta investigating mistakenly submitted Duchenne therapy report

Study participant fell seriously ill

- PMLiVE

Pfizer set to unveil Mylan merger and spin-off

Follows consumer health deal with GSK

- PMLiVE

Otezla scores new indication as speculation over potential buyers grows

Who will buy blockbuster psoriasis drug?

Precision paediatrics: Treating patients with CAR-T

Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...

Blue Latitude Health

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

- PMLiVE

Evotec spins off cancer tech into new Breakpoint company

Will challenge AstraZeneca and others in DNA damage response

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links